The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 320.00
Bid: 323.00
Ask: 324.50
Change: 0.00 (0.00%)
Spread: 1.50 (0.464%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 320.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-FTSE 100 flat as Vodafone loss offsets gains in banks; Oxford Biomedica shines

Tue, 18th May 2021 09:23

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* Oxford Biomedica rises on robust outlook

* Vodafone drops after missing earnings expectations

* FTSE 100 up 0.2%, FTSE 250 adds 0.6%
(Updates with market close)

By Shivani Kumaresan and Devik Jain

May 18 (Reuters) - London's FTSE 100 was little changed on
Tuesday as poor earnings by Vodafone offset gains in bank
stocks, while better-than-expected jobs data strengthened views
of a stronger economic recovery from a pandemic-driven crash
last year.

The blue-chip index rose 0.02%, with banks, mainly
HSBC Holdings, Lloyds Banking Group and
Standard Chartered gaining between 0.8% and 1.5%.

Consumer discretionary stocks, including Compass Group
, Kingfisher and Just Eat Takeaway.com
also provided the biggest boost to the index.

Mobile operator Vodafone Group fell 8.9% on
reporting a 1.2% drop in annual adjusted earnings, as COVID-19
hit roaming revenue and handset sales.

The domestically focussed mid-cap FTSE 250 index
climbed 0.5%.

Britain's unemployment rate fell again, to 4.8% between
January and March, and hiring rose further in April, according
to data that showed employers gearing up for the easing of
coronavirus curbs.

"A third consecutive month of falling unemployment suggests
the peak rate caused by the pandemic wasn't as high as feared",
said Sophie Griffiths, Market Analyst, UK & EMEA at OANDA.

"While the furlough scheme has succeeded in preventing a
wave of redundancies, there is little doubt the jobless rate
will rise again when it concludes in September."

Britain extended its huge job-protecting furlough programme
by five months until the end of September, covering about one in
five private-sector employees who receive 80% of their salary
for hours not worked.

The FTSE 100 has gained nearly 9.4% year-to-date as
investors flocked to energy, materials and banking stocks that
are seen benefiting the most from a stronger economic recovery
due to speedy COVID-19 vaccinations and government support.

Fund managers loaded up on UK stocks and cut exposure to
technology stocks as rising inflation and "taper tantrum" fears
leave growth stocks vulnerable to pull-backs, Bank of America's
May fund manager survey released on Tuesday found.

Among other stocks, Oxford Biomedica gained 10.4%,
to the top of the mid-cap index after it doubled the revenue
expectation from its COVID-19 vaccine supply deal with drugmaker
AstraZeneca.

Imperial Brands rose 1.5% after the tobacco company
reiterated its full-year outlook.
(Reporting by Shivani Kumaresan and Devik Jain in Bengaluru;
editing by Uttaresh.V and Jonathan Oatis)

More News
10 Sep 2020 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
9 Sep 2020 08:31

Oxford Biomedica slumps as AstraZeneca vaccine trial halted

(Sharecast News) - Oxford Biomedica shares slid on Wednesday on news that AstraZeneca and Oxford University's Covid-19 vaccine trial has been put on hold, as investors fretted over how this might affect the gene and cell therapy company's supply deal with the UK pharmaceuticals giant.

Read more
1 Sep 2020 10:27

UPDATE 2-AstraZeneca bolsters COVID-19 vaccine supply with new deal

* AZ reserves production capacity at Oxford Biomedica plant* Deal could be expanded beyond new term of 18 months* AZ's drug, Imfinzi, also wins EU okay for aggressive lung cancer* AZ shares rise 1.5%, Oxford Biomedica up 2% (Adds comment on agreeme...

Read more
1 Sep 2020 10:27

CORRECTED-UPDATE 2-AstraZeneca bolsters COVID-19 vaccine supply with new deal

(Corrects para 3 to say EU (not U.S.) approval for Imfinzi)* AZ reserves production capacity at Oxford Biomedica plant* Deal could be expanded beyond new term of 18 months* AZ's drug, Imfinzi, also wins EU okay for aggressive lung cancer* AZ shares ...

Read more
1 Sep 2020 10:00

UPDATE 2-FTSE 100 falls to 15-week low after best August since 2014

(For a live blog on European stocks, type LIVE/ in an Eikon news window.)* FTSE 100 hit by strong pound, marks worst day since late July* Oxford Biomedica rises as AstraZeneca expands supply tie-up* British factory activity improves in August* Hom...

Read more
1 Sep 2020 08:29

UPDATE: Astra, Oxford Biomedica Expand Covid-19 Vaccine Supply Deal

UPDATE: Astra, Oxford Biomedica Expand Covid-19 Vaccine Supply Deal

Read more
1 Sep 2020 07:54

LONDON BRIEFING: Oxford Biomedica And Astra Expand Vaccine Supply Pact

LONDON BRIEFING: Oxford Biomedica And Astra Expand Vaccine Supply Pact

Read more
1 Sep 2020 07:54

CORRECTED-UPDATE 1-AstraZeneca, Oxford Biomedica expand COVID-19 vaccine supply tie-up

(Corrects currency in second paragraph to pounds from dollars)Sept 1 (Reuters) - AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate, as it looks to scale-up supp...

Read more
1 Sep 2020 07:54

UPDATE 1-AstraZeneca, Oxford Biomedica expand COVID-19 vaccine supply tie-up

(Adds details on supply agreement, background)Sept 1 (Reuters) - AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate, as it looks to scale-up supply ahead of a po...

Read more
1 Sep 2020 07:42

LONDON MARKET PRE-OPEN: Dunelm Sees Rise In Sales From Pent Up Demand

LONDON MARKET PRE-OPEN: Dunelm Sees Rise In Sales From Pent Up Demand

Read more
1 Sep 2020 07:35

CORRECTED-AstraZeneca expands COVID-19 vaccine supply tie-up with Oxford Biomedica

(Corrects currency in first paragraph to pounds from dollars)Sept 1 (Reuters) - AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell t...

Read more
1 Sep 2020 07:35

AstraZeneca expands COVID-19 vaccine supply tie-up with Oxford Biomedica

Sept 1 (Reuters) - AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell therapy firm $15 million upfront and an additional $35 millio...

Read more
3 Aug 2020 08:05

Oxford Biomedica signs deal with Beam Therapeutics

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics, it announced on Monday, which it described as a Massachusetts-based biotechnology company developing precision genetic medicines through the use of base editing.

Read more
31 Jul 2020 11:06

IN BRIEF: Oxford Biomedica And Axovant Sign Clinical Supply Deal

IN BRIEF: Oxford Biomedica And Axovant Sign Clinical Supply Deal

Read more
31 Jul 2020 08:34

Oxford Biomedica signs supply deal with Axovant Gene Therapies

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a three-year clinical supply agreement with a wholly-owned subsidiary of Axovant Gene Therapies, it announced on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.